RYTM Valuation

Rhythm Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

103.270

+1.59(1.564%)1D

Overview
Forecast
Valuation
Earnings

RYTM Relative Valuation

RYTM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RYTM is overvalued; if below, it's undervalued.

Historical Valuation

Rhythm Pharmaceuticals Inc (RYTM) is now in the Overvalued zone, suggesting that its current forward PS ratio of 29.10 is considered Overvalued compared with the five-year average of -11.57. The fair price of Rhythm Pharmaceuticals Inc (RYTM) is between 59.96 to 75.18 according to relative valuation methord. Compared to the current price of 102.45 USD , Rhythm Pharmaceuticals Inc is Overvalued By 36.28%.

Relative Value

Fair Zone

59.96-75.18

Current Price：102.45

36.28%

Overvalued

-35.47

Trailing

Forward

-45.57

EV/EBITDA

Rhythm Pharmaceuticals Inc. (RYTM) has a current EV/EBITDA of -45.57. The 5-year average EV/EBITDA is -8.66. The thresholds are as follows: Strongly Undervalued below -25.15, Undervalued between -25.15 and -16.91, Fairly Valued between -0.42 and -16.91, Overvalued between -0.42 and 7.82, and Strongly Overvalued above 7.82. The current Forward EV/EBITDA of -45.57 falls within the Strongly Undervalued range.

-40.26

EV/EBIT

Rhythm Pharmaceuticals Inc. (RYTM) has a current EV/EBIT of -40.26. The 5-year average EV/EBIT is -9.34. The thresholds are as follows: Strongly Undervalued below -25.57, Undervalued between -25.57 and -17.46, Fairly Valued between -1.23 and -17.46, Overvalued between -1.23 and 6.89, and Strongly Overvalued above 6.89. The current Forward EV/EBIT of -40.26 falls within the Strongly Undervalued range.

29.10

Rhythm Pharmaceuticals Inc. (RYTM) has a current PS of 29.10. The 5-year average PS is 50.64. The thresholds are as follows: Strongly Undervalued below -142.13, Undervalued between -142.13 and -45.75, Fairly Valued between 147.02 and -45.75, Overvalued between 147.02 and 243.41, and Strongly Overvalued above 243.41. The current Forward PS of 29.10 falls within the Historic Trend Line -Fairly Valued range.

-59.49

P/OCF

Rhythm Pharmaceuticals Inc. (RYTM) has a current P/OCF of -59.49. The 5-year average P/OCF is -13.79. The thresholds are as follows: Strongly Undervalued below -42.62, Undervalued between -42.62 and -28.20, Fairly Valued between 0.63 and -28.20, Overvalued between 0.63 and 15.05, and Strongly Overvalued above 15.05. The current Forward P/OCF of -59.49 falls within the Strongly Undervalued range.

-46.66

P/FCF

Rhythm Pharmaceuticals Inc. (RYTM) has a current P/FCF of -46.66. The 5-year average P/FCF is -10.04. The thresholds are as follows: Strongly Undervalued below -25.90, Undervalued between -25.90 and -17.97, Fairly Valued between -2.11 and -17.97, Overvalued between -2.11 and 5.82, and Strongly Overvalued above 5.82. The current Forward P/FCF of -46.66 falls within the Strongly Undervalued range.

Rhythm Pharmaceuticals Inc (RYTM) has a current Price-to-Book (P/B) ratio of -541.77. Compared to its 3-year average P/B ratio of 50.61 , the current P/B ratio is approximately -1170.56% higher. Relative to its 5-year average P/B ratio of 31.52, the current P/B ratio is about -1818.65% higher. Rhythm Pharmaceuticals Inc (RYTM) has a Forward Free Cash Flow (FCF) yield of approximately -1.64%. Compared to its 3-year average FCF yield of -7.89%, the current FCF yield is approximately -79.16% lower. Relative to its 5-year average FCF yield of -14.89% , the current FCF yield is about -88.96% lower.

-545.74

P/B

Median3y

50.61

Median5y

31.52

-1.64

FCF Yield

Median3y

-7.89

Median5y

-14.89

Competitors Valuation Multiple

The average P/S ratio for RYTM's competitors is 8.92, providing a benchmark for relative valuation. Rhythm Pharmaceuticals Inc Corp (RYTM) exhibits a P/S ratio of 29.10, which is 226.17% above the industry average. Given its robust revenue growth of 66.80%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

RYTM.O

Rhythm Pharmaceuticals Inc

Regencell Bioscience Holdings Ltd

Ionis Pharmaceuticals Inc

Jazz Pharmaceuticals PLC

1.68

2.14%

7.47B

Performance Decomposition

Market capitalization of RYTM increased by 118.38% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 29.08M to 48.50M.

The secondary factor is the P/E Change, contributed 64.93%to the performance.

Overall, the performance of RYTM in the past 1 year is driven by Revenue Growth. Which is more sustainable.

66.80%

29.08M → 48.50M

Revenue Growth

-13.35%

-110.95 → -96.14

Margin Expansion

64.93%

-20.41 → -33.67

P/E Change

118.38%